Cipla today informed the stock exchanges that it has received fresh notices from National Pharmaceutical Pricing Authority, Government of India. The company said that it has received further demand notices from the government demanding an amount of Rs 47.7 crore in respect of the drug Salbutamol and an amount of Rs 25.4 crore in respect of the drug Ciprofloxacin.
"These demands are contrary to the orders of the Hon'ble Supreme Court of India and the company has received legal advice that entire amounts demanded by the government are not tenable and sustainable," the company says in a notice to the stock exchanges.